A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares close up 2.64%
12/23/2024 02:08 PM - Society
2 acquitted of endangering flights with drone near Taoyuan Airport
12/23/2024 12:53 PM - Business
Taiwan plans to raise duty-free limit for alcohol to 1.5 liters: MOF
12/23/2024 12:38 PM - Society
Low of 7.3°C recorded Monday in Sanwan amid cold, wet weather
12/23/2024 10:54 AM - Business
U.S. dollar lower in Taipei trading
12/23/2024 10:12 AM